RxSafe Podcast Series

Pharmacies Share the Formula for Improving Patient Health Part TWO | RxSafe

PART TWO
During the 2021 NCPA Annual Conference, Todd Eury leads a panel discussion of Pharmacy Owners who provide insights to leveraging RxSafe technologies in their pharmacies & enhancing patient medication adherence.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacies Share the Formula for Improving Patient Health Part ONE | RxSafe

PART ONE
During the 2021 NCPA Annual Conference, Todd Eury leads a panel discussion of Pharmacy Owners who provide insights to leveraging RxSafe technologies in their pharmacies & enhancing patient medication adherence.
Learn more about your ad choices. Visit megaphone.fm/adchoices

How To Leverage Section 179 & Save on Taxes | RxSafe

The Section 179 tax deduction has helped small businesses offset the cost of capital equipment for years. The dysfunction in Congress has frequently caused the statutory purchase limit to seesaw until just before year-end. But, the good news is the IRS Section 179 purchase price limit of $500,000 was made permanent law in 2016 with the passage of the PATH act.
In 2017 the deduction limit for Section 179 increased to $1 million for 2018 and beyond. The limit on equipment purchases increased to $2.5 million.
Furthermore, the bonus depreciation is: 100%
After calculating your potential Section 179 savings below, call us today at (877) 978-2364 or fill out the form to the right. We’d love to learn more about your pharmacy and let you know the many ways the RapidPakRx can increase your profitability.
Special Guests:
Pharmacy Owner: Aimee Stuermer PharmD
Pharmacy CPA & Accounting Expert: Scotty Sykes w/ Sykes & Company
Pharmacist Financial Planner: Derek Delaney w/ PharmD Financial Planning
Learn more about your ad choices. Visit megaphone.fm/adchoices

Diabetes Care and the Impact of Adherence | RxSafe

Beyond the Vial, Transform Your Pharmacy Series: Diabetes Care & The Impact of Adherence
34.2 million Americans have diabetes. People want reliable information & education on better management of their diabetes. Many people feel challenged in accessing credible information about controlling their diabetes and for those who reside in rural or underserved communities, this issue is compounded. 
Community pharmacies are more accessible to patients than most primary care providers and serve as an ideal setting for the delivery of health education. This webinar & podcast will help pharmacists and pharmacy owners understand the opportunity to build a more robust diabetes management program including education, monitoring, and medication adherence with a goal to provide patients with a positive impact on overall metabolic control.
Panelist Speakers:
Ghada Abukuwaik RPh | Owner at CureMed Pharmacy
Ghada Abukuwaik is the Head Pharmacist, President, and owner of CureMed Specialty Pharmacy in Clifton, NJ. CureMed offers point-of-care testing services and offers a Diabetes Self-Management Education program, as well as workshops on cholesterol management and nutrition, among others.
Dr. Ani Rostomyan PharmD, BCPS, APH
Dr. Ani Rostomyan is a Board-Certified Clinical Pharmacist and Holistic Health Coach specializing in Diabetes management and offers Pharmacogenomics consulting. Dr. Rostomyan has her own functional wellness practice that emphasizes personalized medicine, lifestyle choices, and a holistic guilt-free nutritional approach to health.
Dr. Lisa Faast CEO DiversifyRx
Dr. Lisa Faast is an innovator, an experienced business executive, and a leader in the independent pharmacy industry. With over 20 years of experience as a pharmacy owner, consultant, compounder, and businesswoman, Lisa is passionate about helping independent pharmacy owners thrive by focusing on diversifying and growing revenue streams.
Garry Welch PhD, CSO SilverFern
Dr. Garry Welch is the Co-Founder and Chief Scientific Officer of Silver Fern Healthcare. A foremost expert in the area pf behavior medicine for chronic disease care, Dr. Welch has 30+ years of clinical research experience on behavior change strategies for people with diabetes.
About the PPN:
The Pharmacy Podcast Network is the global leader in podcast content for the Business & Profession of Pharmacy. Since March 2009, the Pharmacy Podcast was the first audio blog for the pharmacy industry and has developed into a directory of over 40+ podcasts with different vertical informational themes.
Collectively, over 2.5M downloads, more than 2,000+ episodes, and 30+ participating Pharmacists and Pharmacy Professionals hosting the podcasts.
SHOW LESS
Learn more about your ad choices. Visit megaphone.fm/adchoices

Understanding the Challenges of Patient Medication Adherence | RxSafe

Background: Positive associations between medication adherence and beneficial outcomes primarily come from studying filling/consumption behaviors after therapy initiation. Few studies have focused on what happens before initiation, the point from prescribing to dispensing of an initial prescription. Objective: to provide guidance and encourage high-quality research on the relationship between beneficial outcomes and initial medication adherence (IMA), the rate initially prescribed medication is dispensed. Using “Initial Medication Adherence” IMA rigorously & include providing convincing evidence that initial prescribing and dispensing events are identified, supplemental parameters incorporating perspective and substitution biases are addressed, and contextual parameters are included. Medications are the most common treatment regimen used in ambulatory health care. Yet, adhering to prescribed medications is a major issue affecting health care because nonadherence has been associated with worsening clinical symptoms and disease progression. Furthermore, medication nonadherence has been linked to increased health care visits, services, and costs. Studies linking nonadherence to these unfavorable outcomes have used various operational definitions for adherence—each with its own nomenclature (e.g., persistence), several representing similar if not exact components of medication adherence, which we call initial medication adherence (IMA). For example: the IMA process begins with a prescriber and patient interaction in an emergency room/ department, hospital, or other clinic setting (step 1) that results in a prescribing event (step 2)—the first of the two key events needed for an IMA measurement. When a prescribing event occurs, data collected from the perspective of either a prescriber or a patient will capture it, whereas data collected from the perspective of a pharmacist will not. To qualify as IMA, however, the prescribing event must relate to a patient’s first prescription within a therapeutic class (step 4). Otherwise, the dispensing event becomes part of a PIMA metric (step 5). Data from either the patient or the prescriber should be able to determine whether the prescribing event is an initial event. The pharmacist becomes aware of prescribing events only when these events are communicated to the pharmacist for filling (step 6). Therefore, the pharmacist does not know how many prescribing events have occurred, only how many have been communicated. However, once the pharmacist receives the prescription (step 7) and fills it (step 8), the pharmacist must dispense the prescription to the patient (step 9). The dispensing event is the second key event needed for measuring IMA (step 10). With dispensing the medication to the patient, both the pharmacist and the patient know that the IMA is achieved, but the prescriber does not. If a pharmacist does not dispense a filled prescription, the prescription becomes abandoned to the pharmacist and is restocked (step 11). If an abandoned prescription is not transferred to another pharmacist (step 12) and subsequently dispensed, the patient will be initially nonadherent (step 13). Either the pharmacist or the prescriber may transfer the prescription from one pharmacy to another, but neither may know that the prescription has been dispensed. — How can pharmacists use the IMA process in communications with physicians? — Explain how pharmacists can educate patients about better adherence with their initial prescriptions—What are the main reasons for medication non-adherence? See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

The Business of Pharmacy TransPharmation | Mark Cuban Cost Plus Drugs

RxSafe & ApproRx have sponsored a gathering of 200+ pharmacy owners interested in learning more about a drug manufacturer interested in working directly with Pharmacy owners. Thanks to Bruce Kneeland and Todd Eury for hosting this LIVE presentation from March 2nd 2021.
Today was the 12th anniversary of the Pharmacy Podcast Network. The 1st podcast about the profession of pharmacy launched episode 1 on March 2nd 2009. Today the PPN has 30+ hosts & is dedicated to the success of our pharmacists & pharmacy techs.
Alex Oshmyansky, MD, PhD is the CEO & Founder at Mark Cuban Cost Plus Drug Company.
Dr. Alex along with strategic investor & business mogul Mark Cuban has launched Mark Cuban Cost Plus Drug Company, a pharmaceutical company that plans to make less expensive versions of selected generic drugs. The company's first drug is a generic version of albendazole, an antiparasitic drug used to treat hookworm. Treated early, two tablets will treat the infection; left untreated, cognitive defects and neurological problems can result.
Cost Plus Drug Company is dedicated to producing low-cost versions of high-cost generic drugs.
In this interview, Dr. Alex pledges to provide radical transparency in how they price their drugs. Dr. Alex has committed letting everyone know what it costs to manufacture, distribute, and market drugs to pharmacies. They will add a flat 15% margin to get wholesale prices. This will help to ensure they remain viable and profitable. There are no hidden costs, no middlemen, no rebates only available to insurance companies. Everybody gets the same low price for every drug they make.
The Pharmacy Podcast Network is the global leader in podcast content for the Business & Profession of Pharmacy. Since March 2009, the Pharmacy Podcast was the first audio blog for the pharmacy industry and has developed into a directory of over 25+ podcasts with different vertical informational themes. Collectively, over 2.5M downloads, more than 2,000+ episodes, and 30+ participating Pharmacists and Pharmacy Professionals hosting the podcasts.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Trusting your Pharmacist, Patient’s Safety, & Prescription Packaging | RxSafe Podcast Series

These days, your patients may be wondering, "How many people touch these pills before I take them?!" COVID-19 has increased pressure on healthcare providers to consider the use of “touchless technology” and other best practices to reduce disease transmission and keep patients safe.
This podcast episode will discuss consumer demand for 'no contact' medication packaging, and how you can differentiate your pharmacy and increase customer loyalty by providing safe, accurate, and untouched prescriptions.
As compliance packaging becomes increasingly popular, pharmacy owners are starting to look at dispensing costs -- not in terms of drug wholesale costs, rebates and DIR fees -- but in terms of vials versus blisters, or vials versus pouches.
After all, reimbursement doesn't change based on the packaging. The patients are prescribed the same NDCs, and their copay is the same regardless of whether the drugs go into a little amber bottle, a 7-day blister pack, or a strip of pouches labeled, ‘morning,’ ‘afternoon,’ and ‘evening.’
But what about your pharmacy costs, and specifically your dispensing costs -- including labor and materials -- for getting the scripts into the patients’ hands?
Regular readers of our blog may remember we already conducted a deep dive into the cost of strip packaging consumables last year. Consumable costs for our RapidPakRx™ strip packaging system are demonstrably lower than competing systems. 
Special Guests: 
Joe Williams, Brisson Pharmacy
Roberta Vining, Riley's Drugs
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Care Collaboration, CureMed Pharmacy & DrFirst Focused on the Patient’s Health | RxSafe Podcasts

Today's podcast is a "Care Collaboration" conversation between a Medical Doctor and a Doctor of Pharmacy, the two most powerful providers in healthcare working together with the patient's health at the center of their focus. 
Thank you to medication adherence technology leaders RxSafe for sponsoring this discussion. Learn more about the innovative technologies at RxSafe.com 
About Ghada Zuhair Abukuwaik, PharmD
Ghada Zuhair Abukuwaik, PharmD  is the President of CureMed Pharmacy. Ghada is a clinical pharmacist who exemplifies experience and expertise, working for over two decades internationally while holding several managerial positions in both pharmacy and hospital backgrounds. Ghada also holds a certificate of pharmacology, working as a team with doctors to consult on dosage, drug interaction and ultimately helping to launch new drugs into the market.
About Dr Tom Sullivan: 
Thomas E. Sullivan, M.D is a board-certified specialist in cardiology and internal medicine with over 40 years of clinical practice. He currently works for DrFirst and sees patients part time in Massachusetts. Dr. Sullivan’s expertise in the application of information technology to health care has helped to create an international standard (ASTM) for the exchange of medical record information called the Continuity of Care Record (CCR). With AMA, he was founding chair of their e-Medicine Advisory Committee, worked with the Physician Consortium for Performance Improvement, represented the AMA and helped create the Physician EHR Coalition and is past chair of the AMA Council on Medical Service. Dr. Sullivan is the physician author of the TEPR Clinical Documentation Challenge. He received the Massachusetts Health Data Consortium’s annual “Investing in Information” award and the Essex County Medical Society “Lifetime Achievement Award” in 2010. He gave Congressional testimony on the impact and value of e-prescribing, and since 2004 has been on the senior management team at DrFirst. DrFirst has been a national pioneer in DEA sanctioned e-prescribing of controlled substances. He is also helping the US Dept. of Commerce as the current Chair of the Healthcare Industry Committee that deals with emerging strategies for “Trusted Identities in Cyberspace.”
Dr. Sullivan graduated from Holy Cross College with an AB in French, having spent a year at the Sorbonne. Pre-med studies were pursued at Harvard and Columbia, and he received his MD from Jefferson in Philadelphia. Dr. Sullivan pursued his Internal Medicine and Cardiology training at St Vincent’s in New York and Tufts New England Medical Center in Boston. He also served in the US Navy as LCDR at the Naval Hospital in Boston/Chelsea during the Vietnam era.
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

The Vitamin Adherence IMPACT (P2) | RxSafe Podcast Series

Today's guest is an incredible pharmacy owner who has embraced change with innovation. Richard Moon is the founder of Pharmacy Innovations. 
Pharmacy Innovations is dedicated to promoting wellness, obtaining and sustaining optimal health and meeting the needs of our community through individualized and customized pharmacy care with compassion, education, service and the highest ethics.
To learn more about RxSafe's technologies to empower your pharmacy, visit: 
https://rxsafe.com/about/ 
 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

The Vitamin Adherence IMPACT (P1) - PPN Episode 961

RxSafe Vitamin Adherence IMPACT Part One
Joe Williams, PharmD., Brisson Drugs Inc
Pharmacy Owner Lumberton, North Carolina
Contact RxSafe 
https://rxsafe.com/contact/ 
References:
Vitamin D is a hormone the kidneys produce that controls blood calcium concentration and impacts the immune system. It is also known as calcitriol, ergocalciferol, calcidiol and cholecalciferol.
Should we really take vitamin D supplements? Is there a connection between low vitamin D levels and cancer? Are you even able to absorb enough from vitamin D supplements? What should our vitamin D levels be? Can adequate vitamin D levels reduce our cancer risk? Can we increase the absorption of vitamin D supplements?
Studies & Resources Prevalence and correlates of vitamin D deficiency in US adults. https://www.ncbi.nlm.nih.gov/pubmed/2...
Taking vitamin D with the largest meal improves absorption and results in higher serum levels of 25-hydroxyvitamin D. https://www.ncbi.nlm.nih.gov/pubmed/2...
Circulating Vitamin D Levels and Risk of Colorectal Cancer in Women. https://www.ncbi.nlm.nih.gov/pubmed/2...
Plasma Vitamin D Concentration and Survival in Colorectal Cancer: Potential Confounding by the Systemic Inflammatory Response http://ascopubs.org/doi/10.1200/JCO.2...
Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. https://www.ncbi.nlm.nih.gov/pubmed/2...
Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. https://www.ncbi.nlm.nih.gov/pubmed/2...
 
 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices